A PYMNTS Company

US: Pfizer accuses Johnson & Johnson of ‘anticompetitive practices’

By  |  September 20, 2017

Pfizer filed a lawsuit against fellow pharmaceutical giant Johnson & Johnson (J&J) over “anticompetitive practices” in a go-for-the-throat showdown involving the drug industry’s treatment of medicines that are similar to the originals, but don’t have the same exact active components.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Pfizer accused J&J of “exclusionary contracts” and price manipulation “to maintain its monopoly” for a drug used to treat rheumatoid arthritis, Crohn’s disease and other afflictions.

    The brawl between Pfizer and J&J centers on the competition between J&J’s Remicade and Pfizer’s biosimilar alternative, Inflectra, which launched in late 2016.

    Pfizer alleged that J&J threatened to withhold rebates from insurers that had determined Inflectra was an acceptable medical alternative to Remicade. The threats, Pfizer alleged, caused insurers to reverse course.

    J&J also offered discounts on Remicade to healthcare providers in exchange for their pledge not to carry Inflectra, Pfizer alleged.

    “These anticompetitive practices are preventing physicians from trying and patients from accessing the biosimilar,” Pfizer said in a statement.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.